Invasion of various carcinoma cells follows their interaction with stromal cells. Hepatocyte growth factor (HGF), four-kringle-containing growth factor, is a mesenchymal or stromal-derived mediator which aects the growth and the invasiveness of carcinoma cells. We now have evidence that a four-kringle-containing antagonist for HGF, HGF/NK4 inhibits invasion of tumors in vivo, as well as in vitro. HGF/NK4 competitively inhibited the binding of HGF to Met/ HGF receptors on GB-d1 human gallbladder carcinoma cells. HGF induced invasion of the cells through Matrigel basement membrane components and into collagen gels, but HGF-induced invasion was inhibited by HGF/NK4. Invasion of GB-d1 cells was induced by co-cultivation with stromal ®broblasts, which mimics tumor-stromal interaction, but it was almost completely suppressed by HGF/NK4. Likewise, invasive growth induced by HGF in collagen gels in GB-d1 cells, HuCC-T1 human cholangiocarcinoma cells, and ME-180 human uterus cervical carcinoma cells was also strongly inhibited by HGF/NK4. When GB-d1 cells were implanted subcutaneously into nude mouse, tumor cells invaded muscular tissue, but the infusion of HGF/NK4 inhibited this invasion. Furthermore, HGF/NK4 increased apoptotic cell death of GB-d1 cells and inhibited tumor growth in vivo. These results indicate that HGF/ NK4 may inhibit growth and invasion of carcinoma cells, as mediated by HGF during tumor-stromal interactions. We propose that there is a unique therapeutic potential for HGF/NK4 to prevent tumor invasion and perhaps even metastasis.
Introduction
Most malignant tumors are carcinomas, and in most cancers, lethality is the result of local invasion and metastasis of neoplastic cells from the primary tumors to other tissues, during tumor progression. The invasive and metastatic characteristics of tumor cells depend on changes in the adhesive properties of tumor cells, degradation of the extracellular matrix (ECM), and a concomitant induction of cell movement (Hart et al., 1989) . Tumor growth also depends on angiogenesis, which again requires ECM degradation and migration of capillary endothelial cells (Folkman, 1989) . Inhibition of a certain process in tumor invasion, metastasis, and angiogenesis may well lead to eective prevention or treatment of cancers.
Although changes in the proto-oncogene and tumor suppresser genes have been shown to lead to cellular transformation by a multistep process, the molecular mechanisms leading to tumor progression are still not clear. There is evidence that stromal cells in¯uence the growth, invasion, and metastasis of tumor cells. The growth, migration, and invasion of tumor cells were markedly accelerated by a broad spectrum of ®broblasts in vivo (Camps et al., 1990) , as well as in vitro (Grey et al., 1989) . In addition to stromal involvement in tumor malignancy, several studies have shown that stromal alteration also occurs during tumor progression, including the existence of`activated' ®broblasts surrounding tumor cells (van den Hoof, 1988; Grey et al., 1989) . Therefore, local and mutual interactions between carcinoma cells and stromal cells, i.e., tumor-stromal interactions, are of particular importance in regulating ECM degradation, invasion, and angiogenesis in tumor tissues.
Accumulating evidence has shown that hepatocyte growth factor (HGF) plays a distinct role in tumorstromal interactions (Tajima et al., 1992; Seslar et al., 1993; Rosen et al., 1994; Matsumoto et al., 1996a; Nakamura et al., 1997; Inoue et al., 1997) . HGF has potent motogenic activity (enhancement of cell movement) on a wide variety of cells, including various types of carcinoma cells, leading to the dissociation, scattering, and migration of cells (Weidner et al., 1990; Jiang et al., 1993a; Matsumoto et al., 1994 Matsumoto et al., , 1996a Jeers et al., 1996; Rosen et al., 1996; Nakamura et al., 1997; Inoue et al., 1997) . Fibroblast-derived factor which induces in vitro invasion of oral carcinoma was identi®ed as HGF (Matsumoto et al., 1994) . Met/HGF receptor of membrane-spanning tyrosine kinase is expressed in a wide variety of tissues (mostly epithelial tissues) and carcinoma cells (Ebert et al., 1994; Di Renzo et al., 1995; Humphrey et al., 1995; Natali et al., 1996; Nagy et al., 1996) , while HGF is expressed in mesenchymal and stromal cells. Importantly, various types of carcinoma cells secrete factors which induce expression of HGF in ®broblasts (Seslar et al., 1993; Rosen et al., 1994; Matsumoto et al., 1996a,b; Nakamura et al., 1997) . Therefore, the mutual interaction between carcinoma cells and stromal ®broblasts, mediated by carcinoma-derived HGFinducers and stromal-derived HGF is likely to be a mechanism, leading to tumor progression. HGF, initially identi®ed and cloned as a potent mitogen for hepatocytes (Nakamura et al., 1984 (Nakamura et al., , 1989 Miyazawa et al., 1989) , is a mesenchymal-(stromal-)derived multipotent factor which exhibits mitogenic, motogenic, and morphogenic activities. Functional coupling between HGF and Met/HGF receptor mediate epithelialmesenchymal (or -stromal) interactions for the development and regeneration of organs and tissues (see reviews, Jiang et al., 1993b; Zarnegar and Michalopoulos, 1995; Matsumoto and Nakamura, 1997) . HGF also has angiogenic activity in vitro and in vivo (Bussolino et al., 1992; Grant et al., 1993) .
Based on these notions, we considered that an antagonistic molecule which abrogates biological activities of HGF might have therapeutic eects to inhibit tumor growth, invasion and metastasis. We recently prepared an HGF-antagonist, designated HGF/NK4', which inhibits mitogenic, motogenic, and morphogenic activities of HGF (Date et al., 1997) . We now report that this HGF-antagonist (HGF/NK4) inhibits growth and invasion of tumor cells both in vitro and in vivo.
Results

Inhibition of HGF binding to the receptor and Met receptor tyrosine phosphorylation by HGF/NK4
In our recent report, we showed that the HGFantagonist, HGF/NK4 inhibits mitogenic, motogenic, and morphogenic activities of HGF, using assay methods widely used to evaluate biological activities of HGF (Date et al., 1997) . In the initial experiments to know the eect of HGF/NK4 on tumor growth and invasion, we addressed whether antagonistic activity of HGF/NK4 would be also seen in tumor cells. To determine whether the HGF-antagonist, HGF/NK4 would competitively block the speci®c binding of HGF to the cell surface receptor, competitive binding analysis was carried out using 125 I-HGF in GB-d1 cells, a human gallbladder carcinoma cell line. Since the Kd value and the number of receptors for binding of HGF on GB-d1 cells were calculated to be 35.4 pM and 684 sites/cell, respectively (data not shown), the GB-d1 cells were incubated in the presence of 40 pM I-HGF. The inhibition by 50% was seen with 400 pM HGF/NK4 and the concentration was 10-fold higher than that of HGF. Taken together, HGF/NK4 seems to competitively bind to the c-Met/HGF receptor with a 10-fold lower anity than that of native HGF.
We then asked whether HGF/NK4 inhibits tyrosine autophosphorylation of Met induced by HGF. GB-d1 cells were serum-starved for 20 h and tyrosine phosphorylation of Met upon addition of HGF and/ or HGF/NK4 was detected after immunoprecipitation and the following immunoblotting ( Figure 1B ). Tyrosine autophosphorylation of Met was detectable 10 min after adding 110 pM HGF, while simultaneous addition of HGF/NK4 and HGF inhibited tyrosine autophosphorylation ( Figure 1B ). HGF/NK4 alone did not induce tyrosine phosphorylation of Met/HGF receptor. Therefore, HGF/NK4 suppresses tyrosine phosphorylation of the c-Met/HGF receptor induced by HGF binding in GB-d1 cells.
HGF/NK4 inhibits invasion stimulated by HGF
Next, to examine whether HGF/NK4 inhibits tumor invasion, we measured the invasion of GB-d1 cells in vitro using a Matrigel invasion chamber and a collagen gel matrix. In the Matrigel invasion chamber, when the invasion of cells is enhanced, cells degrade the extracellular matrix components, and migrate through pores of membrane to the opposite side of the membrane. In the absence of HGF, there was no evidence of invasive cells, however, HGF dosedependently stimulated invasion of GB-d1 cells. Otherwise, HGF/NK4 itself did not stimulate the invasion, but it could block the invasion induced by HGF in a dose-dependent manner. The complete inhibition by HGF/NK4 was seen with a dose of 10 3 -fold higher concentration of HGF (Figure 2 ). HGF/ NK4 also inhibited cell scattering induced by HGF in GB-d1 cells (not shown). Likewise, with regards to growth promoting activity, 110 pM HGF enhanced cell proliferation by 1.34-fold, while the growth promoting activity of HGF was strongly inhibited by 110 nM HGF/NK4 (not shown).
To examine the invasion into the stroma, GB-d1 cells were plated on a collagen gel matrix. Even though GB-d1 cells were established from lymph node metastases and they invaded surrounding tissues when intradermally implanted into athymic nude mice, cells did not invade the collagen gel matrix. However, HGF markedly induced the invasion of GB-d1 cells into collagen gel matrix, when cells were initially plated on collagen gels ( Figure 3A ). HGF/NK4 itself did not induce invasion into the collagen gel rather it almost completely blocked stromal invasion at a 10 3 -fold higher concentration than HGF. Similarly, when GBd1 cells were cultured in the collagen gels, the invasive growth induced by 110 pM HGF was almost completely inhibited by 110 nM HGF/NK4 ( Figure 3B ).
To determine if HGF also induces invasion of other carcinoma cells and to observe if HGF/NK4 would inhibit invasion of cells, HuCC-T1 human cholangiocarcinoma cells and ME-180 human uterus squamous carcinoma cells were cultured in collagen gels ( Figure  4 ). In the absence of HGF, HuCC-T1 cells grew in collagen gels in a spherical multicellular structure, without invasion into gels (Figure 4 ). However, when cultured in the presence of HGF, HuCC-T1 cells invaded the gels multicellularly, which resulted in a branching duct formation in collagen gels. HGF/NK4 itself induced no change in appearance with a dose as high as 110 nM, whereas it almost completely inhibited invasion and branching duct formation of the cells induced by HGF, at a 10 3 -fold higher concentration than HGF. Since HuCC-T1 cells are well-dierentiated carcinoma cells originally derived from human hepatic bile duct, HGF seems to stimulate invasion of the cells, with concomitantly inducing morphogenic response in these cells. ME-180 cells grew in a spherical structure, without invasion into the gel (Figure 4) , whereas in the presence of 110 pM HGF, the cells seemed to gain an invasive potential, which resulted in scattering of cell aggregates and the expression and invasion of cells into the gel. Addition of 110 nM HGF/NK4 alone did not induce such an invasive change, 110 nM HGF/NK4 almost completely inhibited invasive characteristics of ME-180 cells in the presence of 110 pM HGF. These observation indicate that HGF/NK4 inhibits in vitro invasion of distinct types of carcinoma cells.
To know whether the inhibitory eect of HGF/NK4 on invasion and growth of tumor cells might be related to a cytotoxicity or not, GB-d1, HuCC-T1, and ME180 cells were cultured in the absence or presence of HGF/ NK4 for 24 h and the viability of cells was measured by trypan blue dye exclusion. HGF/NK4 did not exhibit signi®cant change in viability of these cells (not shown), indicating that the inhibition of invasion and growth in these tumor cells by HGF/NK4 was not due to cytotoxic eect of HGF/NK4.
Inhibition of GB-d1 cell invasion through tumor-stromal interactions
We used a co-culture method in which ®broblasts derived from gallbladder stroma were cultured in the outer well, while GB-d1 cells were cultured in the Matrigel chamber ( Figure 5A ). We then measured invasion of GB-d1 cells as described above (Figure 5B and C) . This co-culture method mimics the tumorstromal interaction through basement membrane components.
When GB-d1 cells were cultured alone without ®broblasts, GB-d1 cells scarcely invaded, whereas HGF induced invasion of GB-d1 cells. In contrast, GB-d1 cells invaded when they were cultured with ®broblasts. The number of invaded cells was higher than that seen in the presence of 10 ng/ml HGF. Since HGF concentration in the co-culture system was 8 ng/ ml, as measured by enzyme-linked immunosorbent assay, the ®nding suggests that ®broblast might secrete a factor(s) distinct from HGF and such a factor(s) stimulates invasion of the cells in this system. Importantly, HGF/NK4 dose-dependently inhibited the invasion and almost completely inhibited the invasion of the cells at 110 nM ( Figure 5B and C). Since HGF/NK4 almost completely blocked invasion of the GB-d1 cells in co-culture condition, the stimulatory eect of a ®broblast-derived factor(s) is likely to be dependent on the co-existence of HGF, in stimulating invasion of GB-d1 cells. Although we have yet to specify such a ®broblast-derived factor(s), one possible explanation is that ®broblasts might produce a cell motility factor, yet such a factor alone could not induce tumor invasion through basement membrane. In the co-existence of HGF, however, HGF upregulates proteinases responsible for tumor invasion through ECM components, and in this condition, ®broblast-derived motility factor might stimulate Figure 4 Inhibitory eect of HGF/NK4 on invasion of HuCC-T1 and ME-180 cells in collagen gels, as induced by HGF. HuCC-T1 and ME-180 cells were cultured in a collagen gel matrix for 12 days in the absence or presence of 110 pM HGF, 110 nM HGF/ NK4, or 110 pM HGF plus 110 nM HGF/NK4 tumor invasion in an additive manner with HGF. Another possibility is that ®broblasts might produce pro-matrix metalloproteinases (pro-MMPs), but the activation of pro-MMPs might depend on tumorderived proteinase such as uPA. Indeed, HGF strongly stimulates uPA activity in GB-d1 cells.
Inhibition of MMP-9 and urokinase-type plasminogen activator by HGF/NK4
Since gelatinases are involved in tumor invasion, particularly through basement membrane components, we measured gelatinase activity, using GB-d1 cells. Cells were incubated with HGF and conditioned medium was subjected to the zymography. In control culture without HGF, cells secreted MMP-9 (92 kDa gelatinase) ( Figure  6A ), but we could scarcely detect other gelatinases in this condition (not shown). Activity of MMP-9 was dose-dependently stimulated by HGF, however, HGF/ NK4, as well as anti-HGF antibody, inhibited the stimulatory eect of HGF on MMP-9 activity.
Since the possible role of uPA in tumor invasion and activation of pro-MMPs is well recognized (Vassalli et al., 1994) , we also measured uPA activity in conditioned media from GB-d1 cells ( Figure 6B ). As shown in Figure 6B , HGF but not HGF/NK4 strongly stimulated uPA activity, whereas HGF/NK4 almost completely inhibited uPA activity, induced by HGF mostly to the basal level.
In vivo inhibition of tumor growth and invasion
Based on in vitro inhibition of tumor invasion by HGF/NK4, we next examined whether HGF/NK4 would inhibit tumor invasion and growth in vivo (Figure 7) . GB-d1 cells were subcutaneously implanted into nude mice and HGF/NK4 or vehicle alone was continuously infused for 2 weeks into a subcutaneous region near the tumor mass, one week after the implantation. Tumor volume increased rapidly following one week after implantation, however, the increase in tumor volume was strongly inhibited by the infusion of HGF/NK4 ( Figure 7A ). In control tumor tissue infused with vehicle alone, GB-d1 cells invaded surrounding tissues, particularly into muscle tissue ( Figure 7B, a and c) . In contrast, invasion of the tumor cells was not seen in mice infused with HGF/ NK4 ( Figure 7B, b and d) . The similar histological Figure 6 Inhibition of MMP-9 and uPA activities in GB-d1. MMP-9 activity (A) and uPA activity (B) were measured in conditioned media from GB-d1 gallbladder cancer cells. GB-d1 cells were cultured for 24 h in the absence, or presence of HGF and/ or HGF/NK4, and conditioned media were subjected to SDS-PAGE. Anti-HGF antibody (a-HGF Ab) was added to the culture at 10 mg/ml in the presence of 110 pM HGF in (A) observation that the infusion of HGF/NK4 inhibited invasive growth of GB-d1 cells into surrounding tissues was seen in tumor tissues in other mice (not shown).
Tumor growth is generally regulated by a counterbalance between cell proliferation and cell death. To address a mechanism by which HGF suppressed tumor growth, apoptotic cells and proliferating cells were respectively detected by TUNEL method and immunohistochemical staining for PCNA (Figure 8 ). In control tumor tissues, 4.0% of tumor cells underwent apoptotic cells death ( Figure 8A ). When HGF/NK4 was infused into mice, the number of apoptotic cells increased to 11.0%, a value being 2.7-fold higher than that in control tumor tissues. On the other hand, the number of PCNA-positive cells in tumor tissues infused with HGF/NK4 was decreased to 76% of the value in control tumor tissues. The weak inhibitory eect of HGF/NK4 on proliferation of the tumor cells seems to be consistent with in vitro ®nding that HGF enhanced cell proliferation by 1.34-fold, while the weak mitogenic activity of HGF was inhibited by HGF/ NK4 (not shown). Consistent with the increase in TUNEL-positive apoptotic tumor cells in mice infused with HGF/NK4, histological appearance of tumor tissues indicate that a signi®cant population of tumor cells underwent apoptotic cell death in HGF/NK4- Figure 7 Inhibition of growth and invasion of GB-d1 cells in nude mice by infusion of HGF/NK4. Increase in tumor volume (A) and histology of tumor tissues (B) were shown. One week after implantation of GB-d1 cells (5610 6 ) into nude mice, HGF/ NK4 solution or vehicle alone was infused for two weeks into subcutaneous regions near the tumor mass using osmotic pump. Twenty-one days after implantation of the tumor cells, tumors were resected and examined histologically. Five mice were used in each experimental group and values are expressed as mean+s.d. (n=5). In (B), typical appearance of tumor tissues (T) in a control mouse not given HGF/NK4-infusion were shown in a, c, and e, while the appearance in mice given HGF/NK4-infusion were shown in b, d, and f, respectively. Evidence of muscle invasion (arrow) is shown in a and c. Bars represent 500 mm in a and b, and 50 mm in c, d, e, and f, respectively ) into nude mice, HGF/NK4 solution (HGF/NK4) or vehicle alone (control) was infused for two weeks into subcutaneous subcutaneous regions near the tumor mass using osmotic pump. Twenty-one days after the implantation, tumors were resected and subjected to histological analysis. Apoptotic cells and proliferating cells (arrowheads) were respectively detected by TUNEL method and PCNA staining. There was no such a massive apoptosis in tumor tissues in control mice ( Figure 7B , a and e).
Discussion
During malignant progression, tumor cells acquire characteristics that promote metastasis. In the case of carcinomas, these properties include autonomous cell proliferation, invasion through basement membrane and stromal ECM, enhanced cell motility, entering into circulatory system, arrest in target organs, and the formation of a secondary outgrowth. With insight into molecular mechanisms of invasion and metastasis, one can devise ways to block these processes, a prospect that has therapeutic potential for treatment of malignant tumors. In the present study, we demonstrated that a speci®c antagonist for HGF, HGF/NK4 potently inhibited not only in vitro invasion of tumor cells, as induced through co-cultivation with fibroblasts, as well as HGF, but also in vivo growth and tumor invasion into surrounding host tissues.
HGF is proteolytically processed to a heterodimer molecule composed of a 69 kDa a-chain and 34 kDa bchain from a single-chain precursor, and the a-chain contains the N-terminal hairpin domain and subsequent four kringle domains (Nakamura et al., 1989) . Previous studies revealed that the N-terminal hairpin domain, the ®rst kringle (K1), and second kringle (K2) are responsible for high-anity binding of HGF to Met/HGF receptor (Hartmann et al., 1992; Lokker et al., 1992 Lokker et al., , 1993 Okigaki et al., 1992; Mizuno et al., 1994) . Small molecules consist of the N-terminal hairpin domain and K1 or K1K2, designated HGF/ NK1 and HGF/NK2 exist as naturally synthesized variants (Chan et al., 1991; Miyazawa et al., 1991; Cioce et al., 1996) , and these variants have partial agonistic activities (Hartmann et al., 1992; Cioce et al., 1996) . Likewise, HGF/NK3 has no mitogenic activity on endothelial cells, while it stimulates migration of the cells (Silvagno et al., 1995) . Schwall et al., (1995) also reported that heparin induces dimerization of HGF/ NK1 and HGF/NK2 and confer their mitogenic activity. In contrast, we recently found that HGF/ NK4 composed of the N-terminal hairpin domain and four kringle domains has no agonistic activities, in terms of mitogenic, motogenic and morphogenic activities, and the tyrosine phosphorylation of Met/ HGF receptor (Date et al., 1997) . HGF/NK4 binds to the Met/HGF receptor, but competitively inhibits the multiple biological activities of HGF. Moreover, HGF/ NK4 has no biological activities even in the presence of heparin (not shown). While the role of K4 in the antagonistic activity of HGF/NK4 remains to be addressed, HGF/NK4 seems to be the ®rst available complete antagonist for the multiple activities of HGF.
Regulation of cell growth, cell movement, morphogenesis, and accompanying remodeling of ECM is a crucial feature for construction of tissue structures. HGF is a mesenchymal-or stromal-derived mediator which regulates cell growth, cell motility and morphogenesis during tissue formation and repair (see reviews, Zarnegar and Michalopoulos, 1995; Matsumoto and Nakamura, 1997) . Given that various types of carcinoma cells utilize reminiscent mechanisms in epithelial-mesenchymal interactions, HGF might play a role in tumor-stromal interaction, and studies elucidated several mechanisms for the involvement of HGF in tumor progression through tumor-stromal interaction (Matsumoto et al., 1994 (Matsumoto et al., , 1996a Inoue et al., 1997; Nakamura et al., 1997; Yamamoto et al., 1997) . Various types of carcinoma cells produce inducers for HGF in ®broblasts (Seslar et al., 1993; Rosen et al., 1994; Matsumoto et al., 1996a,b; Nakamura et al., 1997) , and enhanced invasive properties by HGF were demonstrated in a wide variety of carcinoma cells (Weidner et al., 1990; Jiang et al., 1993b; Matsumoto et al., 1994 Matsumoto et al., , 1996a Jeers et al., 1996; Rosen et al., 1996; Nakamura et al., 1997; Inoue et al., 1997) . Autocrine activation of the Met/HGF receptor in leiomyosarcoma cells induced enhanced tumorigenicity, invasion and metastasis (Jeers et al., 1996) . If a paracrine or autocrine mode of HGF activation in tumor tissues could be blocked, then the invasive growth of tumors could be inhibited. Our present study demonstrated that the HGF/NK4 inhibits invasive growth of tumor cells both in vitro and in vivo.
HGF activates multiple pathways in target cells, leading to decreased cell-cell adhesions and enhanced cell motility and invasiveness. HGF induces tyrosine phosphorylation of b-catenin (Shibamoto et al., 1994) and focal adhesion kinase (p125 FAK ) (Matsumoto et al., 1994) , and activates rho small GTP-binding protein (Takaishi et al., 1994; Ridly et al., 1995) , events that lead to increased cell motility and dissociation of cellcell interactions. In addition to increased cell motility, activation and/or induction of speci®c proteases which mediate the degradation of ECM components promote tumor invasion. In this context, HGF induces uPArelated proteolysis network in certain types of cells (Pepper et al., 1992) , and Jeers et al., (1996) demonstrated that induction of the uPA proteolysis network by HGF is coupled to enhanced tumorigenecity and invasive and metastatic properties in certain tumor cells. We here found that HGF stimulates MMP-9 and uPA activities in gallbladder cancer and that the induction was blocked by HGF/NK4. It is highly probable that HGF/NK4 inhibits HGF-triggered multiple events that lead to enhanced motility and degradation of basement membrane and ECM components both in vitro and in vivo.
It is noteworthy that infusion of HGF/NK4 suppressed the increase in tumor mass and that HGF/NK4 increased apoptotic tumor cells while weakly decreased proliferating tumor cells. The inhibitory eect of HGF/NK4 on in vivo tumor growth is thus likely to be achieved by both increased apoptosis and decreased proliferation of tumor cells, wherein the increased apoptosis by HGF/NK4 may be more predominant cause for tumor suppression than the decreased cell proliferation. In vivo growth of tumor cells particularly depends on their ability to induce angiogenesis in tumor tissues (Folkman, 1989) and inhibition of tumor angiogenesis results in tumor suppression through inducing apoptosis of tumor cells, rather than inhibiting tumor cell proliferation (O'Reilly et al., 1996) . HGF is known as an angiogenic factor (Bussolino et al., 1992; Grant et al., 1993) and breast carcinoma cells capable of producing HGF induced Cancer prevention by HGF-antagonist K Date et al more extensive angiogenesis in vivo than that seen in parental cells incapable of producing HGF (Lamszus et al., 1997) . Taken together, we speculate that inhibition of angiogenic activity, as well as mitogenic activity of HGF may be the cause for suppression of in vivo tumor growth by HGF/NK4.
Inhibition of tumor invasion and metastasis as well as tumor angiogenesis awaits the development of new strategies in cancer treatment and prevention. Based on the notion that HGF is a mediator in tumor-stromal interactions which confer malignant characteristics in tumor cells, we demonstrated for the ®rst time that the antagonistic molecule for HGF, HGF/NK4 practically inhibits in vivo growth and invasion of a certain type of tumor cells, in experimental animals. Together with ®ndings that the coupling of HGF and Met/HGF receptor aect invasive properties in a wide variety of tumor cells, application of the HGF-antagonist or possibly its gene may provide a new strategy toward cancer prevention.
Materials and methods
Materials
Human recombinant HGF was puri®ed from the conditioned medium of Chinese hamster ovary cells transfected with human HGF cDNA (Nakamura et al., 1989; Seki et al., 1990) . Polyclonal antibody against human HGF was prepared from the serum of a rabbit immunized with human recombinant HGF. IgG was puri®ed using protein A-Sepharose (Pharmacia Biotech, Uppsala, Sweden) and anti-human HGF IgG (1 mg/ml) completely neutralized the biological activities of 1 ng/ml human HGF. HGF/NK4 was prepared by proteolytic digestion with elastase as described elsewhere (Date et al., 1997) . Antiphosphotyrosine monoclonal antibody (PY-20) was obtained from Chemicon International, Inc. (Temecula, CA) and anti-cMet polyclonal antibody (C-12) was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Cell culture
GB-d1 cells were established from surgical specimens from a 58-year-old man with gallbladder cancer (Shimura et al., 1995) . Gallbladder ®broblasts were initially proliferated outward from surgical specimens from a 66-year-old woman with cholelithiasis (unpublished data), and used during at 10 ± 15 passages. ME-180 human cervical epidermoid carcinoma cells and HuCC-T1 human cholangiocellular carcinoma cells were obtained from the Japanese Cancer Research Resources Bank. Cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with streptomycin, penicillin and 10% fetal calf serum (FCS).
Receptor assay
HGF was radioiodinated by the chloramine-T method, as described elsewhere . The speci®c activity of 125 I-HGF was 30 ± 54 mCi/mg protein. GB-d1 cells were cultured on a 24-well plate dish, the cultures were washed once with binding buer (Hanks' solution containing 20 mM HEPES and 2 mg/ml bovine serum albumin, pH 7.0) and equilibrated in the same buer for 30 min at 128C. Ice-cold binding buer containing 40 pM 125 I-HGF, with increasing concentrations of unlabeled HGF or HGF/NK4, was added and the preparation was incubated for 1 h. Cultures were washed three times with ice-cold binding buer, and the 125 I-HGF speci®cally bound to the cells was measured using a g-counter after lysis of the cells with 1 M NaCl. All binding experiments were performed in quadruplicate.
Measurement of in vitro tumor invasion
In vitro invasion of tumor cells was measured using a Matrigel invasion chamber (Becton Dickinson, Bedford, MA) or collagen gel. When using a Matrigel chamber, GBd1 cells suspended in DMEM containing 10% FCS were added to inner cup of a Matrigel invasion chamber at a density of 1610 4 cells/cm 2 and HGF and/or HGF/NK4 were added to the medium of the outer cup. After 24 h cultivation, cells which migrated through Matrigel and ®lter membrane with 8-mm pores were counted after staining with hematoxylin. For co-cultivation of GB-d1 cells and gallbladder ®broblasts, human gallbladder ®broblasts were initially seeded on 24-well plates (Costar) at a density of 10 5 cells/cm 2 and cultured in DMEM containing 10% FCS for 24 h. The medium was changed to fresh medium supplemented with 2% FCS, GB-d1 cells were seeded on the inner cup of 24-well Matrigel invasion chamber at a density of 5610 4 cells/cm 2 and cultured for 24 h.
For invasion assay in a collagen gel, seven volumes of type I collagen solution (Cellmatrix, type IA, Nitta gelatin, Yao, Japan) were mixed with two volumes of ®vefold concentrated DMEM and one volume of FCS, under ice-cooling, added to an inner cup of a Transwell chamber (Costar), and incubated for 10 min at 378C. GB-d1 cells plated on the top of a 1 mm thick collagen gel at a density of 10 5 cells/cm 2 were cultured for 8 h. The medium was replaced with DMEM supplemented with 10% FCS and the cells were cultured in the presence of HGF and/or HGF/NK4 in the medium for 12 days. After ®xing in 70% ethanol, the cells were embedded in paran. Sections were stained with hematoxylin and eosin. Alternatively, GB-d1, ME-180, and HuCC-T1 cells were harvested using trypsin-EDTA solution, suspended in ice-cold 0.2% collagen solution at a density of 10 4 cells/ml, and 500 ml aliquots of cell suspension were added to wells with a 16 mm width (Nunc, Kampstrup, Roskilde, Denmark). After the collagen solution gelled, 500 ml of culture medium containing HGF and/or HGF/NK4 was added to each well. Culture medium was changed every 3 days, and the cells were cultured for 12 days.
Detection of receptor tyrosine autophosphorylation
Tyrosine phosphorylation of Met/HGF receptor was analyzed as described elsewhere (Date et al., 1997) . Brie¯y, serum-starved cells were treated with HGF and/ or HGF/NK4, and washed with phosphate-buered saline (PBS) containing 1 mM Na 3 VO 4 . The cells were extracted in lysis buer composed of 20 mM Tris-HCl (pH 7.4), 10 mM EDTA, 150 mM NaCl, 2 mM Na 3 VO 4 , 5 mg/ml leupeptin, 1 mM phenylmethylsulfonyl¯uoride, and 0.5% Triton X-100, and the lysate was centrifuged at 12 000 g for 10 min. The supernatant was treated with antibody to human cMet and Protein A-Sepharose and the immunoprecipitates were separated by SDS ± PAGE. The proteins were electroblotted onto PVDF membranes (Bio-Rad, Hercules, CA, USA), and probed with anti-phosphotyrosine antibody or anti-c-Met antibody. Proteins reacting with these antibodies were detected using an ECL enhanced chemiluminescence method (Amersham, Little Chalfont, England).
Zymographies for gelatinase and uPA activities
Subcon¯uent GB-d1 cells were washed three times with PBS, and were cultured in serum-free DMEM, with or without HGF and/or HGF/NK4 for 24 h. The conditioned medium was collected and concentrated 10-fold with Centricon-10 concentrators (Amicon, Beverly, MA, USA). For the measurement of gelatinase activity, samples were mixed with SDS sample buer, and subjected to SDS ± PAGE, using 10% polyacrylamide gel containing 1 mg/ml gelatin. After electrophoresis, the gel was washed in 2.5% Triton X-100, and incubated in 50 mM Tris-HCl buer (pH 8.0) containing 0.5 mM CaCl 2 and 1 mM ZnCl 2 for 20 h at 378C. The gel was stained with 1% Coomassie brilliant blue and photographed. For the measurement of uPA activity, cell extracts and culture supernatants were prepared and analyzed by zymography, as described (Vassalli et al., 1984) .
In vivo assay for tumor invasion and histochemical analysis.
Six to 8-week-old male nude mice (BALB/c nu/nu, Japan SLC, Inc., Hamamatsu, Japan) were subcutaneously implanted with 5610 6 GB-d1 cells. After one week, an osmotic pump (Alzet 2002, Palo Alto, CA) containing HGF/NK4 or vehicle alone (10 mM phosphate buer, pH 7.3, containing 1 M NaCl, and 0.01% Tween 80) was surgically implanted near the tumor and HGF/NK4 solution or vehicle was continuously infused for two weeks into the subcutaneous region near the tumor mass. Five mice were used in each experimental group. The size of tumors in all groups was measured using a dialcaliper, and the volume of tumors was determined using the formula width 2 6length60.5. All mice were killed 14 days after osmotic pump implantation (21 days after tumor implantation), the tumors were excised and weighted, then were ®xed in 10% formalin for 1 day and embedded in paran according to standard histological procedures. Sections were stained with hematoxylin and eosin.
To detect apoptotic cells in tumor tissues, tissue sections were stained by a modi®ed TUNEL method, using ApopTag in situ Apoptosis Detection System (Oncor, Gaitherburg, MD). Proliferating cells were detected using antibody against proliferating cell nuclear antigen (PCNA). Tissue sections were treated with anti-PCNA antibody (PC-10, Novocastra Lab., Newcastle), followed by peroxidase-conjugated avidinbiotin complex, using Vectastain Elite ABC kit (Vector, Burlingame, CA, USA). The number of TUNEL-positive apoptotic cells and PCNA-positive proliferating cells were respectively determined by counting more than 1000 nuclei in dierent sections in each animal.
